{"id":666362,"date":"2023-09-05T17:04:01","date_gmt":"2023-09-05T17:04:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=666362"},"modified":"2023-09-05T17:04:01","modified_gmt":"2023-09-05T17:04:01","slug":"allogeneic-hematopoietic-stem-cell-transplant-market-is-expected-to-expand-at-a-healthy-growth-rate-during-the-forecast-period-20232032-key-companies-millennium-sanofi-seres-takeda","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/allogeneic-hematopoietic-stem-cell-transplant-market-is-expected-to-expand-at-a-healthy-growth-rate-during-the-forecast-period-20232032-key-companies-millennium-sanofi-seres-takeda_666362.html","title":{"rendered":"Allogeneic Hematopoietic Stem Cell Transplant Market is Expected to Expand at a Healthy Growth Rate During the Forecast Period (2023-2032)| Key Companies &#8211; Millennium, Sanofi  Seres, Takeda"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\">\n<div><a href=\"https:\/\/www.abnewswire.com\/uploads\/1585648587.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Allogeneic Hematopoietic Stem Cell Transplant Market is Expected to Expand at a Healthy Growth Rate During the Forecast Period (2023-2032)| Key Companies - Millennium, Sanofi  Seres, Takeda\" src=\"https:\/\/www.abnewswire.com\/uploads\/1585648587.jpeg\" alt=\"Allogeneic Hematopoietic Stem Cell Transplant Market is Expected to Expand at a Healthy Growth Rate During the Forecast Period (2023-2032)| Key Companies - Millennium, Sanofi  Seres, Takeda\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/div>\n<div class=\"quotes\">\n<div>DelveInsight Business Research LLP<\/div>\n<\/div>\n<\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">DelveInsight&#8217;s &#8220;Allogeneic Hematopoietic Stem Cell Transplant (Allo-HSCT) Market Insights, Epidemiology, and Market Forecast-2032&#8221; report delivers an in-depth understanding of the Allogeneic Hematopoietic Stem Cell Transplant (Allo-HSCT), historical and forecasted epidemiology as well as the Allogeneic Hematopoietic Stem Cell Transplant (Allo-HSCT) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/div>\n<p style=\"text-align: justify;\">DelveInsight&#8217;s &#8220;<strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/allogeneic-hematopoietic-stem-cell-transplant-allo-hsct-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=dpr\">Allogeneic Hematopoietic Stem Cell Transplant (Allo-HSCT) Market Insights, Epidemiology, and Market Forecast-2032<\/a><\/strong>&#8221; report delivers an in-depth understanding of the Allogeneic Hematopoietic Stem Cell Transplant (Allo-HSCT), historical and forecasted epidemiology as well as the Allogeneic Hematopoietic Stem Cell Transplant (Allo-HSCT) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/p>\n<p style=\"text-align: justify;\"><strong>Allogeneic Hematopoietic Stem Cell Transplant Overview<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong>An allogeneic stem cell transplant uses healthy blood stem cells from a donor to replace bone marrow that&#8217;s not producing enough healthy blood cells. An allogeneic stem cell transplant is also called an allogeneic bone marrow transplant.<\/p>\n<p style=\"text-align: justify;\">A donor may be a family member, an acquaintance, or someone you don&#8217;t know. The blood stem cells used in an allogeneic stem cell transplant can be, collected from the donor&#8217;s blood, collected from the bone marrow within a donor&#8217;s hipbone, collected from the blood of a donated umbilical cord<\/p>\n<p style=\"text-align: justify;\"><strong>Allogeneic Hematopoietic Stem Cell Transplant Epidemiology Insights<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>The reduced NRM translated into decreased overall mortality after transplantation. Overall survival at 1 year after allo-stem Cell Transplant was 54.8% from 1980 through 1989, 57.6% from 1990 through 1999, 67.5% % from 2000 through 2009, and 72.1% from 2010 through 2016.<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>Click here to learn more about the <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/allogeneic-hematopoietic-stem-cell-transplant-allo-hsct-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=dpr\">Allogeneic Hematopoietic Stem Cell Transplant Market Landscape<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>The Report Covers the Allogeneic Hematopoietic Stem Cell Transplant Epidemiology Segmented by:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Allogeneic Hematopoietic Stem Cell transplant-diagnosed cases&nbsp;<\/li>\n<li>Total Allogeneic Hematopoietic Stem Cell Transplant incident&nbsp; cases<\/li>\n<li>Total Allogeneic Hematopoietic Stem Cell Transplant prevalent cases&nbsp;<\/li>\n<li>Allogeneic Hematopoietic Stem Cell Transplant treatment cases&nbsp;<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>Allogeneic Hematopoietic Stem Cell Transplant Market Outlook&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\">The Allogeneic Hematopoietic Stem Cell Transplant (Allo-HSCT) market outlook of the report helps to build a detailed comprehension of the historic, current, and forecasted Allogeneic Hematopoietic Stem Cell Transplant (Allo-HSCT) market trends by analyzing the impact of current Allogeneic Hematopoietic Stem Cell Transplant (Allo-HSCT) therapies on the market, Allogeneic Hematopoietic Stem Cell Transplant (Allo-HSCT) unmet needs, drivers and barriers, and demand for better technology.<\/p>\n<p style=\"text-align: justify;\">This segment gives a thorough detail of Allogeneic Hematopoietic Stem Cell Transplant (Allo-HSCT) market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Allogeneic Hematopoietic Stem Cell Transplant (Allo-HSCT) market data are presented with relevant tables and graphs to give a clear view of the market at first sight. According to DelveInsight, the Allogeneic Hematopoietic Stem Cell Transplant (Allo-HSCT) market in 7MM is expected to witness a major change in the study period 2019-2032.<\/p>\n<p style=\"text-align: justify;\"><strong>Key Companies Working in the Allogeneic Hematopoietic Stem Cell Transplant Market<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Millennium Pharmaceuticals<\/li>\n<li>Sanofi&nbsp;<\/li>\n<li>Seres Therapeutics<\/li>\n<li>Takeda<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">And many others<\/p>\n<p style=\"text-align: justify;\"><strong>Allogeneic Hematopoietic Stem Cell Transplant Therapies Covered and Analyzed in the Report<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Alemtuzumab<\/li>\n<li>Xylitol<\/li>\n<li>Vedolizumab<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\">And many others&nbsp;<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Learn more about the <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/allogeneic-hematopoietic-stem-cell-transplant-allo-hsct-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=dpr\">Key Companies and Emerging Therapies in the Allogeneic Hematopoietic Stem Cell Transplant Market<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Table of Contents&nbsp;<\/strong><\/p>\n<ol style=\"text-align: justify;\">\n<li>Key Insights&nbsp;<\/li>\n<li>Allogeneic Hematopoietic Stem Cell Transplant Introduction&nbsp;<\/li>\n<li>Executive Summary of Allogeneic Hematopoietic Stem Cell Transplant<\/li>\n<li>Disease Background and Overview<\/li>\n<li>Epidemiology and patient population<\/li>\n<li>Allogeneic Hematopoietic Stem Cell Transplant &nbsp; Emerging Therapies<\/li>\n<li>Allogeneic Hematopoietic Stem Cell Transplant &nbsp; Market Outlook<\/li>\n<li>Market Access and Reimbursement of Therapies<\/li>\n<li>Market Drivers&nbsp;<\/li>\n<li>Market Barriers&nbsp;<\/li>\n<li>Appendix<\/li>\n<li>Report Methodology<\/li>\n<li>DelveInsight Capabilities<\/li>\n<li>Disclaimer<\/li>\n<\/ol>\n<p style=\"text-align: justify;\"><strong>Learn about the detailed offerings of the report @<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/allogeneic-hematopoietic-stem-cell-transplant-allo-hsct-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=dpr\"> Allogeneic Hematopoietic Stem Cell Transplant Market Outlook<\/a><\/strong><\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Adya Kaul<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=allogeneic-hematopoietic-stem-cell-transplant-market-is-expected-to-expand-at-a-healthy-growth-rate-during-the-forecast-period-20232032-key-companies-millennium-sanofi-seres-takeda\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> 919650213330<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> Nevada<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/consulting\/due-diligence-services\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/consulting\/due-diligence-services<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/consulting\/due-diligence-services\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=allogeneic-hematopoietic-stem-cell-transplant-market-is-expected-to-expand-at-a-healthy-growth-rate-during-the-forecast-period-20232032-key-companies-millennium-sanofi-seres-takeda\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>DelveInsight Business Research LLP DelveInsight&#8217;s &#8220;Allogeneic Hematopoietic Stem Cell Transplant (Allo-HSCT) Market Insights, Epidemiology, and Market Forecast-2032&#8221; report delivers an in-depth understanding of the Allogeneic Hematopoietic Stem Cell Transplant (Allo-HSCT), historical and forecasted epidemiology as well as the Allogeneic Hematopoietic &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/allogeneic-hematopoietic-stem-cell-transplant-market-is-expected-to-expand-at-a-healthy-growth-rate-during-the-forecast-period-20232032-key-companies-millennium-sanofi-seres-takeda_666362.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,417,406,403,404],"tags":[],"class_list":["post-666362","post","type-post","status-publish","format-standard","hentry","category-Business","category-Marketing-Sales","category-Pharmaceuticals-Biotech","category-UK","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/666362","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=666362"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/666362\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=666362"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=666362"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=666362"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}